BridgeBio Oncology Therapeutics, Inc.BBOT
Key ratios
ROA
-29.8%2025
2024
-59.4%
ROE
-48.2%2025
2024
-111.0%
Recent news
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Track BBOT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer